Is Denali Therapeutics Inc. (DNLI) a Buy, Sell, or Hold?
NASDAQ : DNLI
Denali Therapeutics Inc. — Analyst Ratings
$23.15 USD
$0.13 (0.56%)
- Volume
- 1.44M
- Average Volume
- 1.89M
- Market Capitalization
- $3.67B
- P/E Ratio
- -8.04
- Dividend Yield
- 0.00%
- Price Target
- $36.00
- Year High
- $27.30
- Year Low
- $12.58
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.28
Analyst Consensus Summary
Consensus Rating
Sell
19 Analysts
Rating Score
2/5
Recommendation Strength
Upside/Downside
-35.7%
vs Current Price
Price Target
$36.00
Average TargetPrice Target Range
Lowest Target
$26.00
-11.0% DOWNSIDE
Average Target
$36.00
Median Estimate
Highest Target
$41.00
-43.5% DOWNSIDEAnalyst Breakdown
Overall Consensus: Buy | Total Analysts: 19
| Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|
| 0 | 19 | 0 | 0 | 0 |
Analyst Ratings (Detailed)
| Analyst Company | Analyst Name | Price Target | Price When Posted | Date | Upside/Downside |
|---|---|---|---|---|---|
| Wedbush | Laura Chico | $26 | $25.3337 | 2026-07-13 08:04 AM | 2.6% |
| Stifel Nicolaus | Paul Mattels | $41 | $23.7624 | 2026-06-22 09:26 AM | 72.5% |
| Wedbush | Laura Chico | $23 | $20.11 | 2026-05-08 09:35 AM | 14.4% |
| Jefferies | Andrew Tsai | $40 | $21 | 2026-03-02 05:08 PM | 90.5% |
| Morgan Stanley | Sean Laaman | $40 | $16.95 | 2026-01-08 07:43 AM | 136.0% |
| UBS | Michael Yee | $25 | $17.21 | 2026-01-07 12:41 AM | 45.3% |